People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Other Health Care, Biotechnology, Healthtech, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Exo Imaging, Inc. | — | Other Health Care | Series C | $169.6M | $284.6M | 2024 |
| Lenz Therapeutics, Inc. | — | Biotechnology | Series C | $136.2M | $1.2B | 2020 |
| SpyGlassPharma, Inc. | — | Other Health Care | Series C | $134.8M | $485.1M | 2023 |
| Adagio Medical, Inc. | — | Healthtech | Series C | $81.6M | $128.1M | 2020 |
| Sparrow Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.3M | $386.6M | 2025 |
| Sydnexis, Inc. | — | Other | Series C | $72.3M | $133.2M | 2024 |
Zach Scheiner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zach Scheiner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Olav B. Bergheim | 1 | 13 |
| Kirk Nielsen | 1 | 13 |
| Juliet Bakker | 1 | 9 |
| Clare Ozawa | 1 | 8 |
| David Katz | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| Hugh B. Neuharth | 1 | 7 |
| Mark - Lester | 1 | 6 |
| Klaus Veitinger | 1 | 6 |
| Geoff Pardo | 1 | 6 |
| James Cox | 1 | 6 |
| Juan-Pablo Mas | 1 | 5 |
| Bilal Khan | 1 | 5 |
| PATRICK MOONEY | 1 | 4 |
| TED KOUTOUZIS | 1 | 4 |
| Stefan Larson | 1 | 4 |
| NEAL BHADKAMKAR | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.